Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide studyPer Soelberg Sørensen, Melinda Magyari, Luigi Pontieri et al.|Multiple Sclerosis and Related Disorders|2022Cited by 42
Ocrelizumab treatment in multiple sclerosis: A Danish population‐based cohort studyLuigi Pontieri, Melinda Magyari, Morten Blinkenberg et al.|European Journal of Neurology|2021Cited by 29
Changes in prognosis of the Danish multiple sclerosis population over timeMelinda Magyari, Nils Koch‐Henriksen, Hanna Joensen et al.|Multiple Sclerosis Journal|2022Cited by 21
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiersLars Forsberg, Jan Hillert, Melinda Magyari et al.|Multiple Sclerosis Journal - Experimental Translational and Clinical|2023Cited by 13
Big Multiple Sclerosis Data network: an international registry research networkAnna Glaser, Jan Hillert, Helmut Butzkueven et al.|Journal of Neurology|2024Cited by 12